Robeco Institutional Asset Management B.V. Trims Holdings in Stryker Co. (NYSE:SYK)

Robeco Institutional Asset Management B.V. reduced its holdings in shares of Stryker Co. (NYSE:SYK) by 2.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 153,094 shares of the medical technology company’s stock after selling 3,453 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Stryker were worth $55,121,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Parnassus Investments LLC acquired a new stake in Stryker during the 3rd quarter worth approximately $762,798,000. International Assets Investment Management LLC lifted its holdings in shares of Stryker by 66,967.5% during the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company’s stock worth $308,433,000 after purchasing an additional 852,496 shares during the period. RTW Investments LP purchased a new position in Stryker in the 3rd quarter valued at $143,392,000. State Street Corp increased its stake in Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after buying an additional 316,404 shares during the period. Finally, FMR LLC raised its position in Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after buying an additional 215,782 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SYK shares. Piper Sandler reiterated an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Wells Fargo & Company increased their target price on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday. Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, UBS Group boosted their target price on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $413.45.

Stryker Trading Down 1.1 %

Stryker stock opened at $390.98 on Thursday. The stock has a market cap of $149.05 billion, a PE ratio of 41.91, a P/E/G ratio of 2.68 and a beta of 0.95. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $376.44 and a 200 day moving average price of $361.98. Stryker Co. has a 52 week low of $314.05 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same period last year, the firm earned $3.46 earnings per share. Equities research analysts predict that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is currently 36.01%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.